BiotechTubeBiotechTube
Home/Pipeline/Lebrikizumab

Lebrikizumab

Atopic Dermatitis

Phase 3Active

Key Facts

Indication
Atopic Dermatitis
Phase
Phase 3
Status
Active
Company
Eli Lilly

About Eli Lilly

Eli Lilly is one of the world's largest pharmaceutical companies with over 145 years of experience in developing life-changing medicines. The company has achieved significant recent success with GLP-1 receptor agonists for diabetes and weight management, generating substantial revenue growth. Lilly continues to invest heavily in R&D across key therapeutic areas including diabetes, oncology, autoimmune diseases, and neurodegeneration, with a robust pipeline of innovative treatments in development.

View full company profile

Therapeutic Areas

DiabetesOncologyImmunologyNeuroscienceObesityCardiovascular

Other Atopic Dermatitis Drugs

DrugCompanyPhase
DupixentSanofiCommercial
ASP2408Astellas PharmaPhase 2
KW-6356Kyowa KirinPhase 2
KHK4083Kyowa KirinPhase 2
Opzelura (ruxolitinib cream)Ono PharmaceuticalApproved
ONO-7913Ono PharmaceuticalPhase 2
KT-474Kymera TherapeuticsPhase 2
GRC 27864Glenmark PharmaceuticalsPhase 2
ARQ-234Arcutis BiotherapeuticsPreclinical/Phase 1
STAR-0310BioCryst PharmaceuticalsPhase 1
RezpegaldesleukinNektar TherapeuticsPhase 2b
ZL-1503Zai LabPhase (Early Clinical)